Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseases

Pharmacokinetics and efficacy of Vedolizumab in inflammatory bowel diseases - Pharmacokinetics of Vedolizumab in inflammatory bowel diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045425

Enrollment

Registered

2021-09-08

Start date

2020-02-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis and Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inflammatory bowel disease patient being treated with vedolizumab or scheduled for treatment with vedolizumab

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Clinical remission at 30 weeks from the start of administration	—

Countries

Japan

Contacts

Public ContactTakayuki Imai

Shiga University of Medical Science Division of gastroenterology

hqmed2@belle.shiga-med.ac.jp077-548-2111

Outcome results